Myotonic Dystrophy Clinical Trial
Official title:
Cardiac and Respiratory Prognostic Factors in Patients With Myotonic Dystrophy Type 1
Myotonic dystrophy type 1 (DM1) is the most frequent neuromuscular disease in adults. DM1
patients have an impaired prognosis (mean age of death <60 years) due to cardiac and
respiratory complications.
Our primary objective was to identify cardiac and respiratory prognostic factors in DM1.
1. Patients with genetically proven DM1 who were admitted in Pitié Salpêtrière Hospital
from 2000 and 2010 will be identified. These patients systematically underwent
neurological, cardiac and respiratory investigations.
2. Baseline medical and genetic information will be entered in a dedicated database,
including cardiac and respiratory investigations.
3. The occurence of severe cardiac and respiratory adverse events will also be collected.
4. Statistical analysis will be performed to look for correlations between baseline
patient characteristics and cardiac or respiratory adverse events during follow up.
;
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04624750 -
Open Label Study in Adolescents and Children With Myotonic Disorders
|
Phase 3 | |
| Recruiting |
NCT00082108 -
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
|
||
| Recruiting |
NCT05890833 -
The Risk of Falls Index for Patients With Neuromuscular Disorders
|
||
| Completed |
NCT05027269 -
Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00233519 -
Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)
|
Phase 1/Phase 2 | |
| Completed |
NCT00167609 -
Efficacy and Safety of DHEA for Myotonic Dystrophy
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06411288 -
Global Study of Del-desiran for the Treatment of DM1
|
Phase 3 | |
| Recruiting |
NCT04003363 -
The United Kingdom National Registry for Myotonic Dystrophy
|
||
| Completed |
NCT02375087 -
Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ?
|
||
| Completed |
NCT01406873 -
Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
|
Phase 2 | |
| Completed |
NCT03959189 -
Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1
|
Phase 1 | |
| Completed |
NCT01931644 -
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
|
||
| Recruiting |
NCT00127582 -
RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy
|
Phase 3 | |
| Recruiting |
NCT02398786 -
Myotonic Dystrophy Family Registry
|
||
| Recruiting |
NCT05019625 -
Biomarker Development for Muscular Dystrophies
|
||
| Recruiting |
NCT05020002 -
Extracellular RNA Biomarkers of Myotonic Dystrophy
|
||
| Active, not recruiting |
NCT04616807 -
An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders
|
||
| Active, not recruiting |
NCT05479981 -
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
|
Phase 2 | |
| Terminated |
NCT02315339 -
European Home Mechanical Ventilation Registry
|
||
| Not yet recruiting |
NCT06147414 -
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
|